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Background: Tuberculosis is a human infectious disease caused by the pathogenic 
strains of Mycobacterium Tuberculosis complex. Although effective antibiotics are 
available it continues to be a major global health problem with considerable mortality. 
The risk factors for this outcome are not completely known. The human 
immunodeficiency virus (HIV) co-infection and the development of resistant strains to 
the actual treatment are pointed as important factors. The aim of this study is the 
evaluation of the significant predictors of mortality in tuberculosis patients.  
 
Methods: We performed a retrospective observational study in a University Hospital in 
Portugal, during a three-year period (2011-2013). We included all patients with a coded 
diagnosis of tuberculosis from the Department of adult Pulmonary Medicine and 
Infectious Disease. Clinical variables and data of test results were collected trough the 
hospital patients’ database and patients’ electronic clinical files.  
 
Results: A total of 90 patients were identified and 14 patients died during the follow-up. 
We found a total mortality of 14% at 12 months and 19% at 24 months of follow-up. 
Smoking, HIV, HIV with low CD4 count, anemia, high red cell distribution width 
(RDW) value, neurologic disease, clinical diagnosis and treatment side effects showed 
significance in the unadjusted analysis, but only anemia, HIV with low CD4 count and 
clinical diagnosis were significant (p<0.05) with upon adjustment for confounders. 
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Conclusion: The significant predictors of mortality in our population of TB patients were 
anemia, low CD4+ count in HIV patients and clinical diagnosis. These findings help to 
identify patient groups with high risk of mortality, needing a careful approach.  
 






A Tuberculose é uma doença infeciosa causada pelas estirpes patogénicas do 
complexo Mycobacterium Tuberculosis. Apesar da existência de tratamento antibiótico 
eficaz continua a ser um problema de saúde major à escala global, com uma mortalidade 
considerável. Os fatores de risco para a sua mortalidade não são completamente 
conhecidos. A coinfecção com o vírus da imunodeficiência humana (VIH) e o 
desenvolvimento de estirpes resistentes ao tratamento atual são apontados como fatores 
importantes. O objetivo deste estudo é a avaliação de fatores preditores de mortalidade 
em doentes com tuberculose. 
 
Métodos: Foi realizado um estudo retrospetivo observacional, num Hospital 
Universitário em Portugal, durante um período de estudo de 3 anos (2011-2013). Foram 
incluídos todos os doentes com diagnóstico codificado de tuberculose, internados no 
Serviço de Pneumologia e Infeciologia. As variáveis clínicas e os resultados dos testes 
realizados foram recolhidos através da base de dados do hospital e do processo clínico 
electrónico do doente. 
 
Resultados: Um total de 90 doentes com diagnóstico codificado de tuberculose foram 
identificados, tendo 14 falecido no período de seguimento. Encontrámos uma mortalidade 
global de 14% aos 12 meses e 19% aos 24 meses. O tabagismo, VIH, VIH com contagem 
baixa de CD4, anemia, coeficiente de variação eritrocitário (RDW) alto, doença 
neurológica, diagnóstico clínico e efeitos adversos ao tratamento demonstraram 
significância no estudo não ajustado, mas apenas a anemia, o VIH com contagem de CD4 
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baixa e o diagnóstico clínico foram significativos (p<0.05) após ajuste para os 
confundidores. 
 
Conclusão: Concluímos que os preditores significativos de mortalidade em tuberculose, 
no nosso estudo, foram anemia, contagem de CD4 baixa em doentes VIH positivos e 
diagnóstico clínico. Estes achados ajudam a identificar grupos de doentes com elevado 
risco de mortalidade que necessitam de uma abordagem mais cuidada.  
 
Palavras chave: Tuberculose, mortalidade, preditores, VIH, baixa contagem de 
CD4, diagnóstico clínico, anemia 	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INTRODUCTION 	  
Tuberculosis (TB) is the human infectious disease caused by the pathogenic 
strains of Mycobacterium tuberculosis complex (MBT). The disease affects mostly the 
lungs (pulmonary TB) but every organ can be affected (extra-pulmonary TB). It’s 
estimated that one third of world’s population is infected with Mycobacterium 
tuberculosis and only a minority of them will develop active disease (10%). An early 
progression is considered when active disease is developed during the first year of 
infection (primary tuberculosis). This type of response is uncommon (5% of all cases), 
but more frequent among immunocompromised individuals and children. [1, 2] Most of 
those infected develop a latent TB infection (LTBI), remaining asymptomatic during long 
periods of time. The majority of LTBI cases will not develop active disease in a lifetime, 
however a small part of them show late disease progression with development of active 
disease after decades (postprimary or TB reactivation). This risk of conversion to active 
disease is increased when a patient is immunocompromised. TB affects usually more men 
than women and typically in the productive age groups. [1, 2] 
The cause of TB was identified by Robert Koch in 1882 and effective antibiotics 
have been available for decades now. However the disease remains a major global health 
problem, affecting millions of people worldwide (9.0 million estimated in 2013). [1] 
Although TB is primarily associated with poverty and developing countries, it is a 
significant concern in Europe, especially among vulnerable groups. Portugal has an 
intermediate incidence rate (21.1/100.000 in 2013), higher than the European Union 
(EU)/ European Economic Area (EEA) average (13.5/100.000 in 2012).[3, 4] Most of the 
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reported cases in Portugal come from urban areas and the typical patient is a drug user, 
alcoholic, migrant, homeless and/or prisoner.[4]  
The co-infection with the immunodeficiency virus (HIV) and the emergence of 
multidrug-resistant (MDR, drug-resistance to isoniazid and rifampicin) and extensively 
drug-resistant (XDR, drug-resistance to isoniazid and rifampicin, a fluoroquinolone and 
one injectable drug) strains of Mycobacterium tuberculosis are the main current 
challenges to disease control.[1, 5, 6] Globally in 2013, an estimated 13% of all TB cases 
were HIV-positive (1.1 millions). [1] Portugal has one of the highest prevalence rates of 
co-infection in the European Region (ER) – 14.5% versus an average of 8% in 2013, and 
the HIV-test coverage in TB patients has been decreasing (76.67% in 2013 vs 85% in 
2010). [1, 3, 4]  
Although the mortality rate from tuberculosis has been diminishing (45% since 
1990), this is still the second worldwide leading cause of death from an infectious 
disease. In 2013, 1.5 million people died from TB, including 360.000 HIV-positive (25% 
of all TB deaths). These numbers are unacceptable given that most TB deaths are 
preventable. [1] The risk factors for this outcome are not completely known. The co-
infection with HIV and resistant strains (MDR-TB and XDR-TB) have been well 
described.[1, 7] In HIV patients, the CD4+ lymphocyte count was an important predictor, 
underlining the importance of the immune system function. [8-10] Advancing age, male 
gender, alcohol and/or drug abuse, smoking and comorbidities (including malignancy, 
chronic obstructive pulmonary disease |COPD|, diabetes, liver cirrhosis, anemia, 
neurologic disease and renal disease) were also identified in previous studies [7, 11-13]. 
Clinical and delayed diagnosis, disease severity, treatment side effects, extra-pulmonary 
 8 
TB and previous TB or treatment were also found to be important.[1, 13] Recently, the 
red blood cell distribution width (RDW) emerged as a possible important signal of TB 
severity.[14] Some studies however, suggest that most of TB deaths are due to non-TB 
related causes. [12]  
A better understanding of the determinants/risk factors to TB mortality could help 
in its prevention through aggressive identification and treating high risk individuals. 
Another clear benefit would be improved allocation of public health resources. [7]  
The aim of this study is the evaluation of the significant predictors of mortality in 
tuberculosis patients.  
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METHODS 
Study design and oversight 	  
We conducted a retrospective observational study in a University Hospital in 
Portugal. The study was approved by the Medical School Scientific Board, and the 
requirement for informed consent was waived due to the retrospective nature of the study.  
Study patients 	  
The study included all patients with a coded diagnosis of tuberculosis from the 
Departments of adult Pulmonary Medicine and Infectious Diseases during a three year 
period (2011-2013). The patients were identified through a search of the hospital 
patient’s database. This database contains clinical data from all patients treated at this 
center, including the primary diagnosis, all the coded secondary diagnosis and the main 
performed tests for each patient. 
Data collection 	  
The relevant variables were collected from the hospital patients’ database and the 
patients’ electronic clinical files. Clinical variables included epidemiological 
characteristics (sex, age and job), habits (drug, alcohol abuse and smoking), 
comorbidities, previous TB diagnosis and treatment, organ involvement and duration of 
symptoms before diagnosis. Smoking, alcohol and drug abuse were considered if they 
were present at TB diagnosis. Late diagnosis was considered when achieved more than 
30 days after admission. The patients’ comorbidities were organized in different groups, 
including hepatic disease, history of malignancy, renal disease, neurologic disease, HIV 
infection and anemia. TB type was organized in two groups: pulmonary and extra-
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pulmonary TB. Severe disease was considered when central nervous system or miliary 
forms occurred. 
The data on the test results (at time of diagnosis) included the method of diagnosis 
(culture or pathology vs clinical probability) and results of drug susceptibility testing 
(DST), anemia, RDW value, HIV status and blood CD4+ count (for HIV positive 
patients). Anemia was considered when hemoglobin value was inferior to 11 g/dl and 
RDW alterations when the RDW value was above 14.0%. Low number of CD4+ cells 
was considered less than 500 cells/mm3. DST results were separated as sensible, resistant 
(any resistance), MDR and XDR. Clinical diagnosis was attributed when no confirmation 
(laboratorial/pathological anatomy) of tuberculosis infection was found but treatment was 
started, due to clinical and/or radiological indicators. The data on treatment and evolution 
included the number of admissions, complications and side effects. The date of last 
contact with the Health System (until July 28, 2014) or the date and cause of death (when 
available) were recorded for the survival analysis.  
Statistical Analysis 	  
The statistical analysis was performed using the STATA software package 
version 13.1 (StataCorp, USA). The continuous variables were characterized using 
measures of central tendency (mean) and distribution (standard deviation), and the 
categorical variables were characterized using proportions. The differences in 
quantitative variables between two groups were tested with Students t test for 
independent variables or Wilcoxon rank-sum test, according to normality, as tested by 
Shapiro Wilk. The relationships between categorical variables were tested using chi-
square. A p-value under 0.05 was considered statistically significant.  
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For the survival analysis, the estimated median survival at 12 and 24 months was 
calculated over full data. A univariate analysis was carried on using Log-Rank for sex, 
young age (under 50 years), alcohol abuse, drug abuse, smoking, DST results, extra-
pulmonary TB, prior TB, clinical diagnosis, severe disease, late diagnosis, treatment side 
effects, anemia, high RDW, hepatic disease, history of malignancy, neurologic disease, 
renal disease, HIV status and in HIV group, low CD4+ count. For the multifactorial 
analysis, the factors achieving a 0.2 significance level in the Log-Rank test were used to 
construct an initial Cox Proportional Hazard Model. A step-down procedure was then 
used to select the significant predictors at a 0.05 level. 
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Table 1: Patients’ Epidemiological and Clinical Characteristics 
* Values are expressed as mean ± standard deviation. 
TB, tuberculosis, HIV, human immunodeficiency virus. 
RESULTS	  	  
During the study period, a total 90 TB patients were recorded, including 62 (69%) 
males and 28 (31%) females. The patients’ epidemiological and clinical data are detailed 
in table 1. The mean age was 52.5 ± 17.9 years (range: 20 to 88), with no significant 
differences between genders (53.2 for females and 52.2 to males, p>0.05, t test). Most 
cases had pulmonary forms of TB (74; 82%), and no previous TB history (83; 92%). 
Alcohol abuse was present in 6 (7%) patients, smoking in 17 (19%) and drug abuse in 4 
(4%) (Figure 1). 	  
 
 
 	  	  	   	  	  	  	  
Variable Global (n=90), n (%) 
Gender 62M (69)/28F (31) 
Age  
          mean (years) 52.5±17.9 
          range (years) 20-88 
Alcohol abuse 6 (7) 
Smoking 17 (19) 
Drug abuse 4 (4) 
Extra-pulmonary TB 16 (18) 
Clinical diagnosis 11 (12) 
Previous TB 7 (8) 
Hepatic disease 14 (16) 
History of malignancy 12 (14) 
Renal disease 5 (5) 
Neurologic disease 6 (6) 
Anemia 29 (32) 
HIV  20 (22) 
       Gender 17M (85)/ 3F (15) 
       Age    
              mean (years) 44.3±10.6 
              range (years) 30-77 
        CD4+ count 18 
              mean (cells/mm3) 200.8±212.5 
              range (cells/mm3) 1- 629 
              < 500 cells/mm3 14 (70) 
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Figure 1: Patients’ habits 
Considering comorbidities, hepatic disease was found in 14 (16%) patients, 
neurologic disease in 6 (7%) and renal disease in 5 (6%). History of malignancy was 
present in 12 (13%) patients, anemia in 29 (32%) and HIV infection in 20 (22%). (Figure 
2).  
	  
Figure 2: Patients' comorbidities 
Eleven patients (12%) were treated after presumptive clinical diagnosis, four with 
extra-pulmonary and seven with pulmonary TB, versus 79 (88%) that had laboratory 
confirmation of TB. 	  
Regarding the HIV group the mean age was 44.3 ± 10.6 years, significantly 
different from the non-HIV group 54.8 ± 18.9 years (p<0.05, t test) (Table 2.) There were 
no significant differences in gender distribution between the HIV and non-HIV group 
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(p=0.078, chi-square). The mean CD4+ count was 200.8 ± 212.5 (range: 1 to 629), and 







Considering mortality, a total of 14 patients (3 females and 11 males) died during 
a median follow-up of 15.9 months. The estimated survival for the whole population was 
86.0% (95% CI: 76.12 to 92.05%) at 12 months and 81.1% (95% CI: 69.92 to 88.43%) at 
24 months. For the HIV patients, estimated survival was 84.1% (95% CI: 58.3 to 94.6) at 
12 months and 61.2% (95% CI: 32.1 to 80.9) at 24 months. For non-HIV patients, 
estimated survival was 86.4% (95% CI: 75.3 to 92.7) at both 12 and 24 months. 
The results from the univariate (Log-Rank) and multivariate (Cox Proportional 
Hazards) mortality analysis are detailed in table 3. Upon building a Cox Proportional 
Hazards model the significant predictors were anemia, HIV with low CD4 count and a 
clinical diagnosis. Survival curves, built from the unadjusted analysis, for the whole 
population, for anemia, low number of CD4 count in HIV patients and for diagnosis form 




Group n Mean St. Dev. p-value* 
HIV + 20 44.3 10.57 
0.0189 
HIV- 70 54.84 18.84 
Table 2: Comparison between age in HIV and non-HIV group 
*The p-value was obtained from a Student t test.  
HIV, human immunodeficiency vírus, St. Dev, standard deviation. 
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Alcohol abuse 0.3670 
Drug abuse 0.6809 
Smoking 0.1030 
TB type 0.9476 
Severe 0.9004 
Clinical Diagnosis 0.0589 
Previous TB 0.7902 
HIV 0.0909 
Hepatic Disease 0.6345 
History of malignancy 0.3249 
Renal Disease 0.2881 
Anemia 0.0001 
RDW alterations 0.0198 
Neurologic disease 0.033 
DST 0.4996 
Late Diagnosis 0.3084 
Low CD4 0.0526 
Side effects 0.0694 
Adjusted Analysis** 
Variable p-value 
Clinical Diagnosis 0.037 
Anemia 0.000 
Low CD4 0.030 
 
* Unadjusted results are not adjusted for any confounders. The p-value was obtained from a univariate mortality 
analysis using Log-Rank Test.  
** Adjusted results are mutually adjusted for all variables in the table. The p-value was obtained from a multivariate 
mortality analysis using Cox proportional hazards model.  
 
TB, tuberculosis, HIV, human immunodeficiency virus, RDW, red blood cell distribution width, DST, drug 





Figure 3: Survival curve for whole TB cases. (y-axis starts at 50% for visual effects). 
 
	  
 	  	  Figure 4: Survival curves for patients with and without anemia. (y-axis starts at 50% for visual effects). 
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Figure 5: Survival curves for HIV patients with and without low number of CD4 count. (y-
axis starts at 50% for visual effects).	  
Figure 6: Survival curves for patients with or without diagnosis by culture or pathology. (y-




We evaluated a hospital based Portuguese cohort of tuberculosis patients and 
found that anemia, HIV with low CD4 count and a clinical diagnosis were significant 
mortality predictors. Smoking, high RDW value, neurologic disease and treatment side 
effects showed significance in the univariate analysis, but did not hold upon adjustment 
for confounders.  
We found a total mortality of 14% at 12 months and 19% at 24 months, which is 
higher than reported for Portugal. This mortality may be due to the hospital base of this 
cohort, since hospitals tend to care for more severe patients. A high number of HIV 
patients were also included, possibly explaining higher mortality. 
Anemia was present in 32% of our TB patients, similar to previous studies (32%-
94%).[15, 16] One possible explanation is the condition called anemia of chronic 
diseases, due to the chronic status of TB and HIV infections. In addition, co-infected 
patients (TB and HIV) tend to have lower haemoglobin levels than those with only one 
condition. [17] Iron-deficiency may also be a cause. The presence of anemia at the time 
of TB diagnosis, has been related with higher mortality. [15] This risk is higher when 
other conditions like poor health status, nutritional deficiencies/malnutrition, iron 
deficiency or severe disease are also present. [15, 17] Patients with anemia are also at 
higher risk for TB infection, recurrence and progression, HIV disease progression and 
poor clinical outcomes. [15, 17]  
HIV, and especially HIV with low CD4+ count is associated with severe immune 
suppression, higher probability of TB disease and reactivation of LTBI. These patients 
frequently display disseminated primary and extra-pulmonary TB and have an increased 
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mortality from the disease. In fact, tuberculosis is the leading cause of death in HIV 
patients.[1, 9] The CD4+ T cells have an important role in immunity against tuberculosis. 
Their functions in active TB include the maintenance of the granulomas’ organization, 
with enclosure of mycobacteria and producing INF-y, which is important for macrophage 
activation and infection control. When CD4+ T cells are compromised a deficient 
containment occurs. [18, 19] In addition the diagnosis of TB becomes more challenging 
due to the disease’s atypical presentations. An increased risk of drug interactions 
(antiretroviral therapy and anti-TB drugs), overlapping toxicity and the immune 
reconstitution inflammatory syndrome hinders our capacity for disease control, 
underpinning the higher risk of death. [8]  
Eleven patients from this cohort were treated after presumptive clinical diagnosis, 
four with extra-pulmonary and seven with pulmonary TB. While this may be useful in 
severe disease requiring prompt and aggressive treatment and lead to disease control and 
cure in a number of patients, others may be harmed by such strategy. Importantly, severe 
disease usually occurs in debilitated patients with a higher risk of death or severe 
consequences from inadequate treatment. The World Health Organization (WHO) 
recommends that treatment may be initiated in cases of smear-negative pulmonary 
tuberculosis after two negative sputum smears are collected, chest x-ray findings are 
consistent and the patient has not responded to a trial of broad-spectrum antibiotics. In 
very-ill patients or patients with proven or suspected HIV, if there is a strong clinical 
suspicion, anti-TB treatment may be started.[20] In our study, the lack of a smear, 
culture, or tissue consistent with tuberculosis was associated with a worse prognosis. This 
is probably associated with increased severity in these patients, although inadequate 
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treatment cannot be excluded. These results underline the need for careful clinical 
evaluation of a patient before the start of anti-TB treatment in the absence of 
microbiological proof of infection.  
Approximating 20% of the worldwide population smokes tobacco. An increased 
number of alveolar macrophages has been found in smokers, but they have an impaired 
function, reducing their immune response to MBT.[21] Smoking has been associated 
with a higher risk for TB infection, progression of LTBI to active disease, relapses, poor 
treatment outcomes and higher risk of death. Measures to avoid and control smoking are 
important to reduce TB mortality and reach the other targets of TB control.[11, 21] 
The RDW is part of laboratorial blood routine analysis, measuring the variation of 
red blood cell volume and is an important tool in the evaluation of anemia. Recent studies 
have shown that RDW elevation is related to the prognosis of several diseases 
(congestive heart failure, acute myocardial infection, pulmonary embolism, pneumonia, 
COPD, obstructive sleep apnea syndrome and sepsis). The cause of RDW elevation isn’t 
known but some studies point to the inflammatory status as the main reason. Severe 
pulmonary TB had been associated with higher levels of RDW, when compared to mild 
and moderate cases.[14]  
Adverse reactions to TB treatment are common even with first-line anti-
tuberculosis drugs, leading to patient morbidity and even mortality. When a severe 
adverse reaction is recognized, the responsible drug must be stopped and switched to 
second-line drugs. Second-line drugs are associated with lower effectiveness, more side 
effects and longer treatment which decreases adherence and increases treatment failures, 
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relapses of infection and hospitalizations. Mortality is especially important with drug-
induced hepatitis. [22]  
Neurological disorders, either acute or chronic, have an increased risk of 
pulmonary infections development.[23] Muscle weakness (more frequent in 
neuromuscular disorders), loss of mobility, disability in airway protection with deficiency 
in secretions’ clearance and more need of intubation can possible justify this higher 
risk.[23] Excluding the genetic neurologic diseases, neurological disorders, like dementia 
or stroke, are more frequent in advanced age, leading to a higher risk of infection and 
mortality due to impaired immune function and comorbidities.  
Our data showed that TB was more common among men than women, was more 
prevalent in the economically productive ages groups and HIV patients had TB earlier 
when compared to non-HIV patients, what is in accordance with other studies.[1] 
Generally most of TB deaths occur among men, as in this study, but recent reports from 
the WHO show that deaths in women are rising. [1] 
Advancing age is considered one of the strongest independent risk factors to TB 
death. Late diagnosis, delayed treatment, reduced immune response, frequent underlying 
comorbidities and higher risk of developing adverse drug effects are possible 
explanations. [7, 12, 24] MDR is also a strong independent risk factor due to the use of 
less efficiency drugs, longer treatment, higher risk of adverse drug reactions and 
treatment failure. [7] Male gender, alcohol and/or drug abuse and some comorbidities 
(malignancy, COPD, diabetes, renal failure, liver cirrhosis) were relevant in other studies. 
[7, 12] However we did not find this in our study. The sample size and the observed low 
frequency of these comorbidities and MDR forms in our population are probable 
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explanations. Our study did not show late diagnosis and consequent delayed treatment to 
be important factors to mortality. However a quick diagnosis and treatment remains an 
important factor for success in TB treatment. [12]  
This study has some limitations. As a retrospective study, the data is dependent on 
the quality of the clinical recordings. For most subjects, only the culture collection date 
and not the results date were available, changing the data on the time of diagnosis. 
Finally, this study did not include an analysis of the cause of death, and part of the 
recorded mortality may have been unrelated to TB. 
In conclusion, we analysed the mortality from a Portuguese hospital-based cohort 
of tuberculosis patients and found that the significant predictors of mortality after 
adjustment were the level of haemoglobin, a low CD4 count in HIV patients and 
treatment administration without confirmation of TB infection. Although these findings 
are limited by the retrospective nature of the study and the sample size, they help to 
identify patient groups with high mortality, needing a careful approach. This could also 
help in an improved allocation of TB resources. Smoking prevention campaigns and a 
better HIV test coverage for TB patients are needed for achieving the Millennium 
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